Office of the Director; Notice of Closed Meeting, 44271 [2010-18496]
Download as PDF
<![CDATA[
Federal Register / Vol. 75, No. 144 / Wednesday, July 28, 2010 / Notices
Boulevard, Suite 325, Rockville,
Maryland 20852–3804; telephone: 301/
496–7057; fax: 301/402–0220. A signed
Confidential Disclosure Agreement will
be required to receive copies of the
patent applications.
sroberts on DSKD5P82C1PROD with NOTICES
Therapeutics for the Treatment and
Prevention of Atherosclerosis and
Cardiovascular Disease
Description of Invention: This
technology consists of peptides and
peptide-analogues that enhance
clearance of excess cholesterol in cells
and do not exhibit the cytotoxicity that
has hampered development of similar
potential therapeutics.
Briefly, apolipoprotein A–1 (ApoA–1)
promotes cholesterol efflux from cells
and its concentration is inversely
correlated with atherosclerotic events.
The isolated peptidic component of
ApoA–1 that acts within the cholesterol
secretion pathway is therapeutic
towards atherosclerosis but exhibits
cytotoxic effects. In contrast, our
inventors have derivatized that ApoA–
1 peptide which is both less cytotoxic
and more active than the underivatized
component in initial studies. This
potential therapeutic is similar to high
density lipoprotein (HDL) therapy and
may complement statin-mediated
reduction of pro-atherogenic
lipoproteins.
Potential Applications:
• Treatment and prevention of
atherosclerosis
• Treatment and prevention of
cardiovascular disease, coronary artery
disease, heart attack, stroke, and
inflammation
• Therapeutic or preventative coating
for a heart or vascular implant
• Alternative to HDL therapy
Potential Advantages:
• Enhanced cytotoxicity profile
• Enhanced hydrophilicity profile
• Complements statin-based therapies
• Oral delivery approaches in
development
Development Status: Early stage with
in vitro proof of concept data.
Market: The CDC indicates that heart
attacks account for 26% of deaths in the
United States of which atherosclerosis is
a significant contributing factor or
cause. Global sales for cardiovascular
therapeutics are expected to exceed
$50b in 2010.
Inventors: Amar A. Sethi (NHLBI) et
al.
Patent Status: U.S. Provisional
Application No. 61/265,291 filed 30
Nov 2009 (HHS Reference No. E–047–
2009/0–US–01).
Licensing Status: Available for
licensing.
VerDate Mar<15>2010
19:05 Jul 27, 2010
Jkt 220001
Licensing Contact: Fatima Sayyid,
M.H.P.M.; 301–435–4521;
Fatima.Sayyid@nih.hhs.gov.
Use of Immunosuppressive Agents for
Treatment of Age-related Macular
Degeneration (AMD) and Diabetic
Retinopathy
Description of Invention: AMD
belongs to a group of disorders in which
the immune system may play an
important role. This invention discloses
that patients with AMD gain additional
therapeutic benefit from combination
treatment of immunosuppressive agents
and standard-of-care in comparison to
standard-of-care alone. This invention
slows the progression of choroidal
neovascularization (CNV) and may have
implications for related pathologies,
including diabetic retinopathy. Clinical
data from a small, randomized pilot
clinical trial are available.
Applications:
• A method of treatment for AMD.
• A method of treatment for diabetic
retinopathy.
• A method of treatment for diseases
associated with CNV.
Advantages:
• Likely to be synergistic with
existing therapeutics.
• May enable repurposing of some
exiting immunosuppressive agents.
Development Status: In clinical trials.
Market: An estimated three million
individuals in the United States will
have an advanced form of AMD by 2020
(Klein R et al. The epidemiology of agerelated macular degeneration. Am J
Ophthalmol. 2004;137(3):486–95).
Inventors: Robert B. Nussenblatt and
Frederick L. Ferris (NEI).
Publication: In preparation.
Patent Status: U.S. Provisional
Application No. 61/254,439 filed 23 Oct
2009 (HHS Reference No. E–198–2008/
0–US–01).
Licensing Status: Available for
licensing.
Licensing Contact: Norbert Pontzer,
J.D., Ph.D.; 301–435–5502;
pontzern@mail.nih.gov.
Collaborative Research Opportunity:
The National Eye Institute, Laboratory
of Immunology, is seeking statements of
capability or interest from parties
interested in collaborative research to
further develop, evaluate, or
commercialize the use of
immunosuppressive agents in the
treatment of age related macular
degeneration. This is in light of new
findings that immune mechanisms
appear to be central to the expression of
the clinical disease we know as AMD.
Please contact Alan Hubbs, Ph.D. at
301–594–4263 or hubbsa@mail.nih.gov
for more information.
PO 00000
Frm 00058
Fmt 4703
Sfmt 9990
44271
Dated: July 22, 2010.
Richard U. Rodriguez,
Director, Division of Technology Development
and Transfer, Office of Technology Transfer,
National Institutes of Health.
[FR Doc. 2010–18490 Filed 7–27–10; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Closed
Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable materials,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Advisory Committee
to the Director, NIH.
Date: August 9, 2010.
Time: 2 p.m. to 3 p.m. e.s.t.
Agenda: To review and evaluate grant
applications (Telephone Conference Call).
Place: National Institutes of Health,
Building 31, Conference Room 6, 9000
Rockville Pike, Bethesda, MD 20892.
Contact Person: Lawrence A. Tabak, PhD,
DDS, Acting Director, Division of Program
Coordination, Planning, and Strategic
Initiatives, Office of the Director, National
Institutes of Health, 31 Center Drive,
Building 31, Room 2C39, Bethesda, MD
20892, 301–496–3571,
lawrence_tabak@nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Any interested person may file written
comments with the committee by forwarding
the statement to the Contact Person listed on
this notice. The statement should include the
name, address, telephone number and when
applicable, the business or professional
affiliation of the interested person.
Dated: July 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 2010–18496 Filed 7–27–10; 8:45 am]
BILLING CODE 4140–01–P
E:\FR\FM\28JYN1.SGM
28JYN1
]]>Agencies
[Federal Register Volume 75, Number 144 (Wednesday, July 28, 2010)]
[Notices]
[Page 44271]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2010-18496]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Office of the Director; Notice of Closed Meeting
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App), notice is hereby given of the following
meeting.
The meeting will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable materials, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Advisory Committee to the Director, NIH.
Date: August 9, 2010.
Time: 2 p.m. to 3 p.m. e.s.t.
Agenda: To review and evaluate grant applications (Telephone
Conference Call).
Place: National Institutes of Health, Building 31, Conference
Room 6, 9000 Rockville Pike, Bethesda, MD 20892.
Contact Person: Lawrence A. Tabak, PhD, DDS, Acting Director,
Division of Program Coordination, Planning, and Strategic
Initiatives, Office of the Director, National Institutes of Health,
31 Center Drive, Building 31, Room 2C39, Bethesda, MD 20892, 301-
496-3571, lawrence_tabak@nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Any interested person may file written comments with the
committee by forwarding the statement to the Contact Person listed
on this notice. The statement should include the name, address,
telephone number and when applicable, the business or professional
affiliation of the interested person.
Dated: July 22, 2010.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. 2010-18496 Filed 7-27-10; 8:45 am]
BILLING CODE 4140-01-P
